No Data
China NT Pharma Clarifies Financial Figures in Major Acquisition
NT PHARMA (01011) intends to acquire 58.11% equity of Zhejiang Kangyuan medical instruments for approximately 0.116 billion yuan.
NT PHARMA (01011) announced that on April 28, 2025, the company intends to issue shares to Mr. Lou Yongbin and Mr. Lou Yongjun...
Express News | China NT Pharma - to Purchase 100% of Issued Shares in Yue Hua, Others, for RMB116.2 Mln
The Trump administration plans to impose tariffs on imported Pharmaceuticals, and the U.S. Pharmaceutical Industry warns that it may increase drug costs.
A report commissioned by a trade organization in the USA Pharmaceutical Industry indicates that if the USA imposes a 25% tariff on imported Pharmaceuticals, it could increase the annual Pharmaceutical costs in the USA by nearly 51 billion dollars and raise drug prices by up to 12.9%.
Accelerating recovery? In March, domestic Innovative Drugs investment and financing increased by about 50% year-on-year, and the Hong Kong Stock pharmaceutical Sector collectively surged.
① In March, domestic investment and financing for Innovative Drugs increased by approximately fifty percent year-on-year, how significant is the Bullish impact? ② The Hong Kong stock market's pharmaceutical Sector rose collectively, which stocks are attracting market attention?
Hong Kong stocks in the pharmaceutical sector soared! Kai Medical surged more than 22%. Institutions claim that tariffs have "no impact" on the wave of Innovative Drugs going abroad.
① How do government policy support and the overseas expansion of Innovative Drugs become a new growth engine for Hong Kong stock pharmaceutical companies? ② Why does Zhongtai International believe that tariffs have limited impact on Innovative Drug companies?
China NT Pharma Group Company Limited (HKG:1011) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough
